By Nigam Arora & Dr. Natasha Arora
CYTK is demonstrating good trial data in patients with obstructive hypertrophic cardiomyopathy. The data shows aficamten is superior to the current standard of care beta blockers.
CYTK is a buyout target. To date, 205 Arora portfolio companies have been bought out. Producing a fortune for members who routinely invest in buyout targets. This record is better than firms that charge upwards of $50K per year. With The Arora Report, you get so much more.
Zones
For those following the Good Way, the Buy Now rating is *** (To see the locked content, please take a 30 day free trial).
For those following the Best Way, the buy zone is $*** – $*** to scale in. It is trading at $32.80 as of this writing in the premarket.
The maximum recommended quantity is ***%.
The target zone is $106 – $114.
The mental stop zone is $*** – $***.
Biotechs are high risk high reward positions. As always there is no guarantee of a buyout. For these reasons, it is important to control the position size.
To understand investing in biotechs, please see the “Speculative Positions” section of the Trade Management Guidelines.
Signal Limited is a Signal(s) with a great record in similar situations but does not meet all of the stringent criteria for a Signal. Typically Signal Limited has higher risk-reward compared to a Signal over the short term.
To take a free 30-day trial to paid services to gain access to more opportunities, please click here.
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
